the authors stated that AURELIA (A Study of Bevaczumab [Avastin] Added to Chemotherapy in Patients With Platinum-Resistant Ovarian Cancer) is the first trial to demonstrate a significant progression-free survival benefit of either a combination regimen or a biologic agent in platinum-resistant ovarian cancer. This attractive result confirms that combining single-agent chemotherapy with biologic agents could be a novel strategy in the treatment of platinum-resistant disease.
No takes yet. Share an insight, caveat, or question.
Tomao et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: